- Case Report
- Open Access
Membranous nephropathy with acquired factor V inhibitor: a case report
© KITAMURA et al.; licensee BioMed Central Ltd. 2013
Received: 7 June 2013
Accepted: 18 December 2013
Published: 21 December 2013
Membranous nephropathy is one of the most common causes of nephrotic syndrome in adults. In contrast, acquired factor V inhibitor is a rare bleeding disorder.
A 62-year-old Asian man with a history of cerebral hemorrhage, purpura, eosinophilia and hyper immunoglobulin E syndrome developed proteinuria. The bleeding disorder was diagnosed with acquired factor V inhibitors. A renal biopsy revealed that he suffered from membranous nephropathy with glomerular endothelial damage which is reported to be involved in another factor disorder. After the steroid administration, the coagulation test and proteinuria were improved.
The presence of factor V inhibitors may have been involved in the development of membranous nephropathy.
Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in adults. MN occurs as a primary or secondary renal disease. Secondary MN occurs as a result of autoimmune diseases, infections and malignancies. In contrast, acquired factor V (FV) inhibitor is a rare bleeding disorder that is known to be difficult for physicians to treat because of limited knowledge and its uncertain relationship with autoimmune disease. Here we suggest a relationship between MN and FV inhibitors.
Laboratory analysis data of coagulation time and coagulation factors
Activated partial thromboplastin time
MN is caused by immune complex localization in the subepithelial zone of glomerular capillaries. Beck et al. reported that M-type phospholipase A2 receptor (PLA2R) is a target antigen with idiopathic MN . The Anti- PLA2R autoantibodies in serum samples from patients with idiopathic MN were predominantly of IgG4 subclass, which is the predominant immunoglobulin subclass seen in glomerular deposits of patients with MN. However, the Anti- PLA2R autoantibodies were not exclusively found in secondary MN. In renal biopsy of this patient, we could not observe the deposits of IgG4 subclass (Additional file 3: Figure S3). We could not find any causes of secondary MN such as malignancy, infections or drugs. These results suggested that the MN in this patient may be involved other immune disorders.
On the other hand, there have been some reports of acquired factor inhibitors complicated by nephrotic syndrome [2–4]. In addition, there have been reports that factor VIII-related antigen and tissue plasminogen activator may be involved in the glomerular endothelial damage in another factor disorder . There is a possibility that coagulopathies may be related to the occurrence of renal disorders with glomerular endothelial cell damages. In this patient, we observed dense subepithelial deposition and the detachment of endothelial cells in the glomerulus upon electron microscopic analysis. It may be suggested that the characteristic finding of membranous nephropathy with acquired factor inhibitors is the presence of damage of the glomerular endothelial cells and lamina rara layer, with high-density deposits at the subepithelium in the glomerulus. Frigui et al. reported that the eosinophils are associated with MN . Renal disorders with eosinophils were caused by several diseases such as drugs, cholesterol embolization, immunoallergic responses et al. . Giudicelli et al. described that most secondary renal disorders in hyperphils are usually due to an immuno-allergic process leading to deposit of immune complexes in glomeruli. Taken together, we reported that membranous nephropathy complicated with factor V inhibitor. The presence of FV inhibitors should be taken into consideration when patients are diagnosed with nephrotic syndrome and MN by renal biopsy because there is some possibility that the FV inhibitors can lead to serious bleeding complications.
We reported a case of membranous nephropathy with acquired factor V inhibitor. The renal pathology revealed the presence of damage of the glomerular endothelial cells and lamina rara layer, with high-density deposits at the subepithelium in the glomerulus. It is important that membranous nephropathy may be complicated with acquired factor V inhibitor if the pathology is observed.
Written informed consent was obtained from the patient for publication of this Case Report and any accompanying images. A copy of the written consent is available for review by the Editor-in-chief of this journal.
- Beck LH, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ: M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med. 2009, 361: 11-21. 10.1056/NEJMoa0810457.PubMedPubMed CentralView ArticleGoogle Scholar
- Takahashi H, Fuse I, Abe T, Yoshino N, Aizawa Y: Acquired factor V inhibitor complicated by Hashimoto’s thyroditis, primary biliary cirrhosis and membranous nephropathy. Blood Coagul Fibrinolysis. 2003, 14: 87-93. 10.1097/00001721-200301000-00016.PubMedView ArticleGoogle Scholar
- Verghese P, Darrow S, Kurth MH, Reed RC, Kim Y, Kearney S: Successful management of factor IX inhibitor-associated nephrotic syndrome in a hemophilia B patient. Pediatr Nephrol. 2013, 28: 823-826. 10.1007/s00467-012-2397-0.PubMedView ArticleGoogle Scholar
- Chang H, Chen YM, Dunn P: Factor VIII inhibitor associated with nephrotic syndrome. Haemophilia. 2007, 13: 766-10.1111/j.1365-2516.2007.01467.x.PubMedView ArticleGoogle Scholar
- Imai C, Kakihara T, Iwabuchi H, Tanaka A, Furukawa T, Uchiyama M: Glomerular vasculopathy after unrelated cord blood transplantation. Pediatr Nephrol. 2003, 18: 399-402.PubMedGoogle Scholar
- Frigui M, Hmida MB, Jallouli M, Kechaou M, Frikha F, Bahloul Z: Membranous glomerulopathy associated with idiopathic hypereosinophilic syndrome. Saudi J Kidney Dis Transpl. 2010, 21: 320-322.PubMedGoogle Scholar
- Giudicelli CP, Didelot F, Duvic C, Desrame J, Herody M, Nedelec G: Eosinophilia and renal pathology. Med Trop (Mars). 1998, 58: 477-481.Google Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.